{
  "report_rows": [
    {
      "kpi": "System-wide RevPAR Growth (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~+3.0% vs. cons +3.38%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adj. EBITDA (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1,050M vs. cons $1,039M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Diluted EPS - Operating (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~$2.30 vs. cons $2.28",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 RevPAR Growth (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide ~2-3% vs. cons +2.79%",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY 2026 Adj. EBITDA (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide ~$4,020-4,060M vs. cons $4,054M",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY 2026 Diluted EPS - Operating (FY 2026)",
      "prediction": "LOWER",
      "answer": "guide ~$8.79-8.91 vs. cons $8.98",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": -1.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -3.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 sell-side cuts FY EPS estimates as guide range ($8.79-8.91) remains below consensus ($8.98); implicit H2 EBITDA cut of ~$25M drives continued underperformance",
  "day5_confidence": "MEDIUM"
}